Preclinical News and Research

RSS

Study reveals the genetic underpinnings of a rare and aggressive ovarian cancer

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

9 Jun 2025

Gene editing can trigger inflammatory, senescence-like responses in blood stem cells

Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using CRISPR-Cas9 in combination with AAV6 vectors can trigger inflammatory and senescence-like responses in blood stem cells, compromising their long-term ability to regenerate the blood system.

5 Jun 2025

FDA approves ENCELTO implant to preserve sight in people with macular telangiectasia type 2

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have been no FDA-approved (or other) treatments to slow or stop vision loss.

4 Jun 2025

Integrating discoveries with translational science to transform Alzheimer's care

At the 12th annual Helen and Robert Appel Alzheimer's Disease Research Institute Symposium, scientists and clinicians shared their latest research which is advancing how Alzheimer's disease is diagnosed and treated.

4 Jun 2025

Switching to a low fat diet slows pancreatic precancer development in mice

Pancreatic cancer is one of the deadliest forms of cancer, killing 87% of patients within five years. Previous studies have shown that obesity can increase pancreatic cancer risk by around 50%.

4 Jun 2025

Y chromosome loss linked to poor cancer outcomes

When cancer cells in male patients and immune cells in their tumors both lose the Y chromosome, those patients tend to experience poorer outcomes than patients without Y chromosome loss, according to new findings from Cedars-Sinai investigators.

4 Jun 2025

LabGenius Therapeutics appoints Dr. Angus Sinclair as Chief Scientific Officer

LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize complex therapeutic antibodies, including those with multispecific designs.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Exercise after chemo key for colon cancer survival, study finds

Post-chemotherapy exercise significantly boosts disease-free survival in colon cancer patients, underscoring the importance of structured physical activity.

3 Jun 2025

PfSPZ-LARC2 malaria vaccine advances to new age groups after successful safety review

Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.

3 Jun 2025

Myeloid cells shape tumor microenvironments and influence cancer progression

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic resistance.

3 Jun 2025

How soy and gut microbes alter cancer treatment results

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes.

2 Jun 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

New peptide therapy shows promise against glioblastoma recurrence

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

29 May 2025

Immune microRNAs drive new frontiers in cardiovascular disease research

Cardiovascular diseases (CVDs) continue to dominate global mortality statistics, with immune dysregulation emerging as a central feature in their pathogenesis.

28 May 2025

Oral 8-aminoguanine protects aging eyes and preserves vision in preclinical study

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly reducing oxidative stress and inflammation. These findings highlight the promise of 8-AG as a non-invasive intervention to slow age-related retinal degeneration.

27 May 2025

Traditional South Asian medicinal plants show promise in addressing memory disorders

The growing global population of elderly individuals has led to a dramatic rise in chronic diseases, including neurocognitive disorders such as Alzheimer's disease.

27 May 2025

Alzheimer’s blood biomarkers predict faster muscle strength loss in older adults

A large Swedish cohort study found that elevated blood biomarkers associated with Alzheimer’s disease—including p-tau217, p-tau181, neurofilament light chain, and GFAP—predict accelerated muscle strength decline over 12 years in dementia-free older adults. These findings suggest that early identification of Alzheimer’s-related biomarkers could help clinicians intervene sooner to prevent sarcopenia and related adverse outcomes in aging populations.

27 May 2025

University of Houston receives $3 million to set up a Cancer Immunotherapy Biomarker Core

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding groundbreaking projects, has awarded the University of Houston $3 million to set up a Cancer Immunotherapy Biomarker Core.

27 May 2025

Preclinical News and Research

Study reveals the genetic underpinnings of a rare and aggressive ovarian cancer

Gene editing can trigger inflammatory, senescence-like responses in blood stem cells

FDA approves ENCELTO implant to preserve sight in people with macular telangiectasia type 2

Integrating discoveries with translational science to transform Alzheimer's care

Switching to a low fat diet slows pancreatic precancer development in mice

Y chromosome loss linked to poor cancer outcomes

LabGenius Therapeutics appoints Dr. Angus Sinclair as Chief Scientific Officer

Navigating the dual role of B cells in tumor immunity

Exercise after chemo key for colon cancer survival, study finds

PfSPZ-LARC2 malaria vaccine advances to new age groups after successful safety review

Myeloid cells shape tumor microenvironments and influence cancer progression

How soy and gut microbes alter cancer treatment results

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

New peptide therapy shows promise against glioblastoma recurrence

Immune microRNAs drive new frontiers in cardiovascular disease research

Oral 8-aminoguanine protects aging eyes and preserves vision in preclinical study

Traditional South Asian medicinal plants show promise in addressing memory disorders

Alzheimer’s blood biomarkers predict faster muscle strength loss in older adults

University of Houston receives $3 million to set up a Cancer Immunotherapy Biomarker Core

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics